Steven Pieper Sells 5,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00. Following the completion of the sale, the insider owned 1,361,053 shares of the company’s stock, valued at approximately $11,568,950.50. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $147,900.00.

Xeris Biopharma Stock Performance

XERS stock opened at $8.33 on Friday. The firm has a market cap of $1.52 billion, a PE ratio of -75.73 and a beta of 0.66. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The business has a 50 day moving average of $7.86 and a 200-day moving average of $6.81. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a positive return on equity of 158.10% and a negative net margin of 5.12%. As a group, sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new position in Xeris Biopharma during the fourth quarter worth about $25,000. KBC Group NV purchased a new stake in shares of Xeris Biopharma during the 1st quarter valued at approximately $27,000. Allworth Financial LP bought a new position in Xeris Biopharma in the 2nd quarter worth approximately $34,000. State of Wyoming bought a new position in Xeris Biopharma in the 2nd quarter worth approximately $52,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after buying an additional 7,421 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on XERS shares. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Xeris Biopharma has a consensus rating of “Hold” and a consensus price target of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.